Encouraging Safety Data for Investigational NTRX-07 Therapy for Alzheimer Disease Targeting Cannabinoid Type 2 Receptor

In a phase 1b clinical trial, short-term treatment with NTRX-07 (NeuroTherapia, Cleveland, Ohio), an investigational small molecule targeting the cannabinoid type 2 (CB2) receptor, was associated with favorable pharmacokinetic and safety data in a small group of healthy volunteers and a subset of 8 participants with early-stage Alzheimer disease (AD). The results of the study were presented at the 16th annual Clinical Trials on Alzheimer Disease (CTAD) conference.

NTRX-07 is a small molecule that is administered orally to target the CB2 receptor involved in neuroinflammation, which is a process increasingly thought to be associated with AD and other neurologic conditions. In the phase 1b double-blind, randomized study, 32 participants received either placebo or NTRX-07 at 10 mg, 30 mg, or 90 mg for 7 days. A cohort of 8 of these participants had diagnosed early-stage AD. Treatment with all dose ranges of NTRX-07 showed a favorable safety profile, with mild or transient adverse events and no dose-limiting or serious adverse events.